Settled

Do GIP/GLP-1 & amylin agonists improve glycemic control versus placebo?

Mostly studied in obesity & overweight. Also asked against other treatments.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

Very likely. So far, established.

NoUnsureYes
Belief
0.88 (range 0.66–0.98)
Trials for
15
Trials against
2
Inconclusive
0

Already under way

The evidence so far

Registered trials
117
With posted results
30
Published papers
6

Of 268 decided analyses: 208 favor gip/glp-1 & amylin agonists, 33 find no difference, 27 favor the comparator.

Papers

Trials

See every trial in the evidence map →